S&P 500   2,612.13 (-99.20%)
DOW   22,150.97 (+5.22%)
QQQ   191.98 (+4.70%)
AAPL   253.10 (+4.84%)
FB   159.97 (+3.76%)
MSFT   160.26 (+4.18%)
GOOGL   1,145.28 (+4.54%)
AMZN   1,945.80 (+2.06%)
CGC   14.18 (+7.02%)
NVDA   262.25 (+7.52%)
BABA   194.68 (+4.04%)
MU   45.31 (+9.92%)
GE   7.24 (+6.47%)
TSLA   515.06 (+7.30%)
AMD   45.71 (+7.33%)
T   28.83 (+4.99%)
ACB   0.85 (+4.94%)
F   4.65 (+9.42%)
NFLX   373.34 (+3.20%)
BAC   21.29 (+6.29%)
GILD   76.83 (-1.76%)
DIS   97.56 (+3.92%)
PRI   88.23 (+9.34%)
S&P 500   2,612.13 (-99.20%)
DOW   22,150.97 (+5.22%)
QQQ   191.98 (+4.70%)
AAPL   253.10 (+4.84%)
FB   159.97 (+3.76%)
MSFT   160.26 (+4.18%)
GOOGL   1,145.28 (+4.54%)
AMZN   1,945.80 (+2.06%)
CGC   14.18 (+7.02%)
NVDA   262.25 (+7.52%)
BABA   194.68 (+4.04%)
MU   45.31 (+9.92%)
GE   7.24 (+6.47%)
TSLA   515.06 (+7.30%)
AMD   45.71 (+7.33%)
T   28.83 (+4.99%)
ACB   0.85 (+4.94%)
F   4.65 (+9.42%)
NFLX   373.34 (+3.20%)
BAC   21.29 (+6.29%)
GILD   76.83 (-1.76%)
DIS   97.56 (+3.92%)
PRI   88.23 (+9.34%)
S&P 500   2,612.13 (-99.20%)
DOW   22,150.97 (+5.22%)
QQQ   191.98 (+4.70%)
AAPL   253.10 (+4.84%)
FB   159.97 (+3.76%)
MSFT   160.26 (+4.18%)
GOOGL   1,145.28 (+4.54%)
AMZN   1,945.80 (+2.06%)
CGC   14.18 (+7.02%)
NVDA   262.25 (+7.52%)
BABA   194.68 (+4.04%)
MU   45.31 (+9.92%)
GE   7.24 (+6.47%)
TSLA   515.06 (+7.30%)
AMD   45.71 (+7.33%)
T   28.83 (+4.99%)
ACB   0.85 (+4.94%)
F   4.65 (+9.42%)
NFLX   373.34 (+3.20%)
BAC   21.29 (+6.29%)
GILD   76.83 (-1.76%)
DIS   97.56 (+3.92%)
PRI   88.23 (+9.34%)
S&P 500   2,612.13 (-99.20%)
DOW   22,150.97 (+5.22%)
QQQ   191.98 (+4.70%)
AAPL   253.10 (+4.84%)
FB   159.97 (+3.76%)
MSFT   160.26 (+4.18%)
GOOGL   1,145.28 (+4.54%)
AMZN   1,945.80 (+2.06%)
CGC   14.18 (+7.02%)
NVDA   262.25 (+7.52%)
BABA   194.68 (+4.04%)
MU   45.31 (+9.92%)
GE   7.24 (+6.47%)
TSLA   515.06 (+7.30%)
AMD   45.71 (+7.33%)
T   28.83 (+4.99%)
ACB   0.85 (+4.94%)
F   4.65 (+9.42%)
NFLX   373.34 (+3.20%)
BAC   21.29 (+6.29%)
GILD   76.83 (-1.76%)
DIS   97.56 (+3.92%)
PRI   88.23 (+9.34%)
Log in

NYSE:EWEdwards Lifesciences Stock Price, Forecast & News

$190.58
+1.51 (+0.80 %)
(As of 04/6/2020 10:22 AM ET)
Add
Compare
Today's Range
$189.55
Now: $190.58
$196.21
50-Day Range
$157.23
MA: $202.67
$235.31
52-Week Range
$154.52
Now: $190.58
$247.64
Volume279,304 shs
Average Volume2.28 million shs
Market Capitalization$39.85 billion
P/E Ratio38.58
Dividend YieldN/A
Beta0.81
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; Acumen Hypotension Prediction Index, an advanced algorithm that indicates the likelihood of a patient developing hypotension; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Read More
Edwards Lifesciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP28176E10
Phone949-250-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.35 billion
Cash Flow$6.15 per share
Book Value$19.89 per share

Profitability

Net Income$1.05 billion

Miscellaneous

Employees13,900
Market Cap$39.85 billion
Next Earnings Date4/28/2020 (Estimated)
OptionableOptionable

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.


Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

How has Edwards Lifesciences' stock been impacted by COVID-19 (Coronavirus)?

Edwards Lifesciences' stock was trading at $197.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EW stock has decreased by 1.4% and is now trading at $194.7049. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Edwards Lifesciences?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Edwards Lifesciences.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Edwards Lifesciences.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) issued its quarterly earnings data on Thursday, January, 30th. The medical research company reported $1.46 earnings per share for the quarter, missing analysts' consensus estimates of $1.49 by $0.03. The medical research company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. Edwards Lifesciences had a return on equity of 31.73% and a net margin of 24.08%. The business's revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter last year, the business posted $1.17 earnings per share. View Edwards Lifesciences' earnings history.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $6.15-6.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.98. The company issued revenue guidance of $4.6-5.0 billion, compared to the consensus revenue estimate of $4.70 billion.

What price target have analysts set for EW?

22 equities research analysts have issued twelve-month price targets for Edwards Lifesciences' stock. Their forecasts range from $175.00 to $300.00. On average, they expect Edwards Lifesciences' stock price to reach $249.33 in the next twelve months. This suggests a possible upside of 28.1% from the stock's current price. View analysts' price targets for Edwards Lifesciences.

What are Wall Street analysts saying about Edwards Lifesciences stock?

Here are some recent quotes from research analysts about Edwards Lifesciences stock:
  • 1. According to Zacks Investment Research, "Edwards Lifesciences exited the fourth quarter of 2019 on a mixed note with lower-than-expected earnings and a revenue beat. Globally, TAVR procedures increased on strong therapy adoption across all geographies. We are also upbeat about strong sales growth within the Critical Care segment, driven by robust demand for the HemoSphere advance monitoring platform and continued adoption of Smart Recovery. The company continued benefiting from its CASMED acquisition. Moreover, a lifted 2020 EPS guidance raises investors’ optimism on the stock. In the past year, shares of Edwards Lifesciences have outperformed the industry. Meanwhile, dismal performances within Surgical Structural Heart and TMTT segments raise concern. Also, escalating costs put pressure on the margins in the fourth quarter." (2/3/2020)
  • 2. BTIG Research analysts commented, "As we cautioned in our Q1 preview, TAVR results missed Street estimates. While we have no doubt that the underlying market remains strong, results have been light for 4+ quarters now, making us question if the market growth is a tad less than expected or if share is slightly shifting. Even so, management maintained an upbeat tone and there was no change to TAVR guidance but with Boston Scientific’s (BSX, Lotus approved in the U.S. tonight, we have to think that combined with weak Q1 results, shares may see pressure. On longer-term drivers, mitral sales were $4M in Q1 and although early feedback on PASCAL has fostered management’s own confidence in its outlook, we feel hitting $40M in revenue this year is a lofty goal. On the positive side, we would point to management’s bullishness on the revenue ramp in 2H and the solid expense control driving the EPS beat." (4/24/2019)

Has Edwards Lifesciences been receiving favorable news coverage?

News headlines about EW stock have been trending very negative this week, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Edwards Lifesciences earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutEdwards Lifesciences.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,322,900 shares, an increase of 7.5% from the February 27th total of 2,160,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.1% of the company's shares are short sold. View Edwards Lifesciences' Current Options Chain.

Who are some of Edwards Lifesciences' key competitors?

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Broadcom (AVGO), Mastercard (MA), UnitedHealth Group (UNH) and Micron Technology (MU).

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 66)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)
  • Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. Controller
  • Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Bath Savings Trust Co (0.01%) and Fulton Bank N.A. (0.00%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View institutional ownership trends for Edwards Lifesciences.

Which major investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N.A.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem, and William J Phd Link. View insider buying and selling activity for Edwards Lifesciences.

Which major investors are buying Edwards Lifesciences stock?

EW stock was bought by a variety of institutional investors in the last quarter, including Bath Savings Trust Co. View insider buying and selling activity for Edwards Lifesciences.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $194.70.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $40.72 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $5.57 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe. View additional information about Edwards Lifesciences.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is http://www.edwards.com/.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel